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Abstract The virus-induced activation of interferon K/L (IFN-
K/L) gene transcription is essential for host defense. The IFN-L
promoter is controlled primarily by the virus-inducible enhancer
elements, the IRF-Es. Here we show that IRF-3, an IRF family
transcription factor, translocates to the nucleus from the
cytoplasm upon virus infection in NIH/3T3 cells. The nuclear
IRF-3 is phosphorylated, interacts with the co-activators CBP/
p300, and binds specifically to the IFN-L IRF-E. Furthermore,
overexpression of IRF-3 causes a marked increase in virus-
induced IFN-L mRNA expression. Thus, IRF-3 is a candidate
transcription factor mediating the activation of the IFN-L gene.
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1. Introduction
The type I interferons (IFN-Ks/L) are a structurally related
family of cytokines which are produced in a variety of cells
upon viral infection [1,2]. Previous studies have demonstrated
that the IFNs have dual functions in antiviral responses: they
confer cellular resistance against virus replication in unin-
fected cells [1,2], while inducing apoptosis in the infected cells
[3]. Another class of IFN, the type II IFN (IFN-Q), which is
structurally unrelated to type I IFNs, displays similar antiviral
function. Expression of IFN-Q is not induced by virus and is
restricted to distinct lymphocyte populations, e.g. mitogen-ac-
tivated Th1-type T cells and interleukin-12-induced natural
killer cells [4]. Thus, IFN-K/L primarily control the initial,
innate immune response against viral infections, and IFN-Q
is presumably more important in the regulation of the late,
adaptive immune response [4].
The IFN-K/L genes are strictly under transcriptional con-
trol. Numerous studies have focused on the mechanisms by
which the IFN-L gene is transcriptionally activated upon viral
infection of the cells [1,2]. It is well established that several cis-
acting DNA elements exist within the promoter region of the
IFN-L gene, and that these elements bind transcription factors
such as IRF-1, IRF-2, ISGF3, NF-UB, AFT-2, c-Jun and
others [5^10]. In particular, much attention has been focused
on the elements which function as virus-inducible enhancer
elements, which we originally termed IRF-Es [11]. In fact,
mutation in the IRF-Es results in a dramatic reduction of
the virus inducibility of the IFN-L promoter [12]. These
IRF-Es overlap with the PRDI and PRDIII elements identi-
¢ed by others [13,14] and show close similarity to the inter-
feron-stimulated response element (ISRE) which is found in
many of the IFN-inducible genes [15].
Several factors have been shown to bind speci¢cally to the
IRF-Es of the IFN-L promoter, which include the IRF family
members of the transcription factors, IRF-1, IRF-2 and p48
(ISGF3Q) [6,7,16]. Gene targeting studies have revealed that
the regulation of these elements is complex and controlled by
multiple factors. Brie£y, induction of the IFN-K/L genes is
dependent on IRF-1 in cells induced by double-stranded
RNA, poly(I):poly(C), but independent of this factor in cells
infected with the Newcastle disease virus (NDV) [17,18]. On
the other hand, gene induction is upregulated, albeit modestly,
in cells lacking IRF-2, an observation consistent with the pre-
vious notion that IRF-2 functions as a repressor [16,17]. More
recently, it has been shown that the virus-induced, full expres-
sion of IFN-K/L genes requires p48 in the context of ISGF3 (a
heterotrimeric complex consisting of p48, Stat1 and Stat2
[15]), which is activated by the initially produced IFNs in
virally infected cells [19]. Thus, ISGF3 functions as a mediator
of the positive feedback regulation of the IFN system. Given
these ¢ndings, it is obviously important to elucidate the nature
of the factor(s) which initially triggers the induction of these
IFN genes.
Several other IRF family members have been identi¢ed
which include IRF-3, IRF-4 and ICSBP (IFN consensus se-
quence binding protein) [20^23]. Among them, IRF-3 is po-
tentially an interesting candidate since it is constitutively ex-
pressed in many cell types and binds to ISRE [20]. However,
little is known about the function of IRF-3 in virus-induced
IFN gene expression.
In this paper, we studied the role of IRF-3 in the expression
of the IFN-L gene in NIH/3T3 cells. We show that IRF-3
normally resides in the cytoplasm and it is translocated to
the nucleus upon NDV infection of the cells. Furthermore,
we provide evidence that this translocation is accompanied
by phosphorylation of IRF-3, which is essential for speci¢c
binding to the IFN-L-derived IRF-E. Finally, we demonstrate
the activation of the IFN-L promoter by IRF-3. These results
suggest that IRF-3 plays a key role in the initiation of IFN-L
gene induction in virally infected cells.
2. Materials and methods
2.1. Construction of expression vectors
HA-IRF-3/pBabe, the retrovirus expression vector for HA-tagged
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mouse IRF-3, was constructed as follows. Mouse IRF-3 cDNA was
obtained by RT-PCR of the total RNA from mouse embryonic ¢bro-
blasts, cloned into the pCRII (Stratagene) vector (pIRF-3), and the
nucleotide sequence of the cDNA was con¢rmed. Sense (5P-AGAG-
CATGGAAACCCCGAAAC-3P) and antisense primers (5P-TCAGA-
TATTTCCAGTGGCCTG-3P) were used for the RT-PCR. The
cDNA was excised by BamHI and XbaI digestion and cloned with
linker oligo nucleotides (5P-GGCCACGAGGTTCAG-3P and 5P-
GATCCTGAACCTCGT-3P) into the NotI and XbaI sites of pEF/
HA vector which has the EF (elongation factor) promoter followed
by a sequence encoding 10 amino acids of in£uenza virus hemagglu-
tinin peptide (HA). The sequence of the linker DNA was con¢rmed
and the EcoRI fragment of HA-IRF-3 cDNA was cloned into the
retrovirus vector, pBabe-puro [24]. The KpnI-XbaI fragment from
pIRF-3 was cloned into the HindIII-XbaI site of pActC [16] to
make pAct3. Part of the DNA binding region (from the SacII site
to the BamHI site, amino acids 7^36) was deleted in pAct3dN.
2.2. Cell culture and retrovirus infection
NIH/3T3 cells were cultured in Dulbecco’s modi¢ed Eagle’s me-
dium supplemented with 10% FCS. Transfection of HA-IRF-3/pBabe
or control pBabe-puro into Bosc23 cells and infection of the retro-
viruses were performed as described [25]. 72 h post infection, the
retrovirus-infected NIH/3T3 cells were cultured in the presence of
2.5 Wg/ml of puromycin to select the cells expressing the viral genes.
2.3. Immuno£uorescent staining and immunoblotting analysis
The staining assay was carried out as described previously [26].
Brie£y, 4U104 NIH/3T3 cells expressing HA-IRF-3 (3T3/IRF-3)
were cultured on a chamber slide. After 12 h of NDV infection, cells
were ¢xed with 4% paraformaldehyde and permeabilized with 0.2%
Triton X-100. HA-IRF-3 was detected with mouse monoclonal anti-
HA antibody (1 Wg/ml; clone 12CA5, Boehringer Mannheim) and
FITC-conjugated anti-mouse IgG antibody.
Immunoblotting analysis was done with anti-HA antibody (0.8 Wg/
ml) and horseradish peroxidase-linked anti-mouse IgG antibody
(Amersham) according to the published procedure [26]. The signals
were detected by enhanced chemiluminescence (Renaissance, NEN
Life Science Products).
2.4. EMSA (electrophoretic mobility shift assay)
Preparation of nuclear extracts and EMSA were performed as de-
scribed [6,19,27]. Binding reaction was incubated for 30 min at 25‡C
in the presence of 0.35 Wg of salmon sperm DNA and 0.2 Wg of
poly(dI):poly(dC). For some samples, the reaction mixture was pre-
incubated with antibodies at 4‡C for 1 h. Anti-human IL-2 receptor
Q-chain antibody was used as a control antibody.
2.5. RNA blotting
The RNA blotting method and the probe DNAs for IFN-L and L-
actin have been described [16]. The HindIII fragment from pIRF-3
was used as IRF-3 probe. Speci¢c activity of each probe was around
1U109 cpm/Wg.
2.6. Luciferase assay
Two micrograms of reporter plasmid were co-transfected with ex-
pression vectors (pAct3 or pAct3dN) and 2 mg of DEAE-dextran into
2U105 NIH/3T3 cells. The total amount of expression vector was
adjusted to 2.0 Wg with pActC. Cells were infected by NDV after 48
h of transfection and harvested 18 h after infection. The luciferase
assay was carried out as described previously [19].
3. Results
3.1. Translocation of IRF-3 from the cytoplasm to the nucleus
upon NDV infection
We ¢rst constructed a retrovirus expressing an HA-tagged
mouse IRF-3 to readily monitor the behavior of IRF-3 during
the course of NDV infection. The retrovirus was infected into
NIH/3T3 cells (referred to as 3T3/IRF-3 cells thereafter). We
¢rst examined the localization of the tagged IRF-3 in 3T3/
IRF-3 cells before and after NDV infection by immuno£uo-
rescence staining. As shown in Fig. 1A, the HA-tagged IRF-3
protein is localized in the cytoplasm in the absence of virus
infection. Upon NDV infection, the protein was found to be
accumulated in the nucleus (Fig. 1A). To determine the ki-
netics of this nuclear translocation after NDV infection, we
prepared nuclear extracts from 3T3/IRF-3 cells before and
after NDV infection, and performed immunoblotting analysis
using anti-HA antibody. As shown in Fig. 1B, the amount of
IRF-3 protein in the nuclear fraction is dramatically increased
12 h after NDV infection, at which time the IFN-L mRNA
starts accumulating (see below).
3.2. Speci¢c binding of the nuclear IRF-3 from NDV-infected
cells to the IFN-L-derived IRF-E
Next, we tested the binding of IRF-3 in the nuclear fraction
of the NDV-infected 3T3/IRF-3 cells to the IRF-E of the
IFN-L promoter. The nuclear extracts were prepared from
the cells expressing HA-IRF-3 12 h after NDV infection or
mock infection, and subjected to EMSA using IRF-E from
the mouse IFN-L gene as a probe. As shown in Fig. 2, a
shifted band is detected in the nuclear extract of the NDV-
infected cells, but not in mock-infected cells (lanes 1, 2). Im-
portantly, this band was super-shifted by incubation with
anti-HA antibody (lane 3), suggesting that it is the HA-tagged
IRF-3 which participates in the formation of this complex in
response to NDV infection. This virus-inducible factor is pre-
sumably complexed to other protein(s), hence tentatively
termed V-IRF-3 thereafter (see below). Next, we tested the
binding speci¢city of V-IRF-3 to the IFN-L-derived IRF-E
by performing competition EMSA. As shown in Fig. 2, the
shifted band is no longer detectable when incubated with an
excess of unlabeled IRF-E probe or ISRE sequence from the
ISG15 promoter (lanes 6, 9). On the other hand, this compe-
tition was not observed with the same amount of unlabeled
DNA containing UB or GAS sequence (lanes 8, 10). These
results suggest that V-IRF-3 binds to the IFN-L-derived
IRF-E in a sequence-speci¢c manner. In addition, the IRF-
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Fig. 1. A: Localization of IRF-3 before and after NDV infection.
HA-tagged mouse IRF-3 was detected with an anti-HA monoclonal
antibody and visualized by FITC-conjugated anti-mouse IgG anti-
body. The picture shows some representative cells. B: IRF-3 is
translocated to the nucleus during the course of NDV infection. Ex-
tracts from the same number of nuclei at indicated times after NDV
infection were loaded on 10% SDS-polyacrylamide.
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E containing two base substitutions within the PRDI region
showed a markedly reduced ability to compete with the native
sequence for binding to V-IRF-3 (lane 7). It has been shown
previously that introduction of these mutations in the IFN-L
promoter results in a dramatic reduction of the promoter
activity [12], an observation consistent with the notion that
the binding of V-IRF-3 is critical for virus-induced promoter
activation.
3.3. Phosphorylation of IRF-3 and its interaction with the
co-activator CBP/p300
Previously, it has been demonstrated that IFN-L gene in-
duction by virus requires post-transcriptional events including
protein phosphorylation [19]. In this context, the nuclear IRF-
3 protein from NDV-infected 3T3/IRF-3 cells was found to
migrate more slowly than IRF-3 found in the cytoplasm in
SDS-PAGE analysis (Fig. 3A, lanes 1^3), suggesting a mod-
i¢cation(s) of IRF-3 in the infected cell nucleus. To test
whether or not this modi¢cation involves phosphorylation,
the nuclear extract from NDV-infected cells was incubated
with calf intestinal alkaline phosphatase (CIAP) and the sub-
jected to immunoblotting and EMSA. As shown in Fig. 3A
(lane 4), the slowly migrating signal disappeared and the in-
tensity of the fast migrating signal, which is found in the same
position as cytoplasmic IRF-3, was signi¢cantly increased
after CIAP treatment. Moreover, the V-IRF-3 binding activ-
ity was not detected after CIAP treatment of the nuclear ex-
tract (Fig. 3B, lane 3). These results suggest that IRF-3 is
phosphorylated after virus infection and its phosphorylation
is essential for the V-IRF-3 binding to IRF-E.
Recently, it was shown that the IFN-L promoter activation
involves CBP/p300, co-activators of transcription which inter-
act with a variety of transcription factors [28]. We examined
whether or not CBP is involved in the formation of V-IRF-3.
As shown in Fig. 3C, EMSA revealed that the V-IRF-3/DNA
complex was partially reacted with anti-pCBP antibody (clone
A-22, Santa Cruz) (lane 2) and the band was eliminated com-
pletely with another antibody, which reacts with CBP and
p300 (clone 451, Santa Cruz) (lane 4). The result therefore
suggests the involvement of CBP/p300 in the formation of
V-IRF-3.
3.4. E¡ect of IRF-3 on IFN-L gene induction by virus infection
The above observations prompted us to investigate the ef-
fect of IRF-3 overexpression on the induction of the endoge-
nous IFN-L gene by RNA blotting analysis. The 3T3/IRF-3
cells were infected with NDV, and total RNAs were prepared
at each time point. Total RNAs were similarly prepared from
cells infected by a control retrovirus (referred to as 3T3/con-
trol cells). As shown in Fig. 4A, the endogenous IRF-3 gene is
constitutively expressed and it is induced by NDV in both
3T3/IRF-3 and 3T3/control cells. In addition, in the 3T3/
IRF-3 cells, the level of HA-IRF-3 mRNA is approximately
12 times higher than that of endogenous IRF-3 gene. IFN-L
mRNA induction is detectable in both 3T3/IRF-3 and 3T3/
control cells 12 h after virus infection (Fig. 4B), at which
nuclear translocation of IRF-3 is also detectable (Fig. 1B).
Notably, IFN-L mRNA induction levels are much higher in
3T3/IRF-3 cells during the course of infection. In fact, the
mRNA level is about 5-fold higher compared to that of
3T3/control cells at 16 h after infection (Fig. 4B). These re-
sults strongly suggest that IRF-3 is involved in the activation
of IFN-L gene transcription. Similar results were also obtained
for the IFN-K genes, suggesting that IRF-3 also acts on these
genes (data not shown). To investigate further the role of
IRF-3 in the activation of the IFN-L promoter, we employed
a transient assay using a reporter gene consisting of the IFN-L
promoter (containing 125 bp upstream region [12]) and luci-
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Fig. 3. E¡ect of CIAP treatment and anti-CBP or CBP/p300 anti-
bodies. A: Western blotting. Nuclear extracts containing 2 Wg of
protein from NDV-infected cells were treated with 38 units of
CIAP. Detection of HA-IRF-3 was done as in Fig. 1B. B: Nuclear
extracts from NDV-infected cells were treated with or without
CIAP. EMSA was performed using the IRF-E probe as in Fig. 2.
One unit of CIAP was used for the treatment of 1 Wg protein of nu-
clear extract. Lane 1: no treatment; lane 2: mock treatment; lane
3: CIAP treatment. C: The nuclear extracts were mixed with 0.4 Wg
of anti-CBP or CBP/p300 antibodies and subjected to EMSA.
Fig. 2. DNA binding activity of IRF-3 to IRF-E. Nuclear extracts
containing 5 Wg of protein were used for each binding reaction. La-
beled oligonucleotide containing the IRF-E sequence from the
mouse IFN-L promoter was used as a probe. The 3T3/IRF-3 cells
were infected with NDV for 12 h or mock-infected and nuclear ex-
tracts were prepared. 0.4 Wg of antibody was incubated with extract
before the binding reaction (lanes 3, 4). In the competition assay,
100 times molar excess of unlabeled oligonucleotides was included
in the binding reaction (lanes 5^10).
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ferase gene (p-125luc). As shown in Fig. 4C, luciferase activity
was signi¢cantly augmented when p-125luc was co-transfected
with an IRF-3 expression vector. Furthermore, this activation
was suppressed by co-expressing a cDNA for the inactive
form of IRF-3 which lacked a part of the DNA binding do-
main.
4. Discussion
Virus-induced expression of IFN-K/L is one of the essential
aspects of the innate immune response [29]. In fact, the IFNs
confer resistance against a wide variety of viruses in unin-
fected cells [1,2]. In addition, it has been shown recently
that IFN-K/L selectively induce apoptosis in virally infected
cells [3], revealing a novel antiviral function of these cyto-
kines. The expression of the IFN-K/L genes is tightly regulated
at the transcriptional level, and virus infection of the cells
results in prompt induction of gene transcription. Among
many regulatory cis-elements found in the promoter of these
genes, one element which is of particular interest is IRF-E
(PRD-I, PRD-III [13,14]), which is commonly found in the
IFN-K and -L promoters. In this regard, we and others have
shown that ISGF3, which is activated by IFN signaling, is a
crucial regulator of IRF-E [7,19]. In fact, ISGF3 was found to
bind to IRF-E, and signi¢cant reduction of NDV-induced
IFN-K/L mRNA expression was observed in mouse embryonic
¢broblasts (EFs) de¢cient in the p48, Stat1, or IFN receptor
genes [6,19]. These results suggest the operation of a positive
feedback mechanism, in which ISGF3 is involved in the late
phase of gene induction followed by the initial phase of IFN
production by an as yet unknown mechanism(s) [19].
In the present study, we have examined the role of IRF-3,
an IRF family member which is constitutively expressed in a
variety of cell types in the regulation of IFN-L gene transcrip-
tion, by expressing an epitope-tagged IRF-3 (HA-IRF-3) in
NIH/3T3 cells. Our results demonstrate that IRF-3 undergoes
translocation from cytoplasm to nucleus upon virus infection.
Concomitantly with this translocation, IFN-L mRNA induc-
tion was observed (Figs. 1B and 4B), suggesting a functional
role for IRF-3 in IFN-L gene transcription. Although NDV
induction of IFN-K genes is much lower in 3T3/control cells, it
is signi¢cantly augmented in 3T3/IRF-3 cells (data not
shown), suggesting that IRF-3 may also be involved in IFN-
K regulation.
Unlike the cytoplasmic IRF-3, the virus-induced nuclear
IRF-3 is phosphorylated, and appears to interact with the
co-activators CBP/p300 (Fig. 3A,C). This nuclear IRF-3,
termed V-IRF-3, speci¢cally binds to IRF-E, and it is possible
that other factors may also be involved in the formation of
the V-IRF-3 complex. Our result that a mutated IRF-E which
has lost its function in the context of the IFN-L promoter
cannot bind V-IRF-3 suggests the critical role of V-IRF-3.
In fact, overexpression of IRF-3 in NIH/3T3 cells results in
a marked upregulation of IFN-L mRNA induction (Fig. 4B).
Furthermore, the virus-induced activation of the IFN-L pro-
moter is enhanced by the expression of IRF-3 in the transient
co-transfection assay, and this enhancement is suppressed by
co-expression of the mutant IRF-3 lacking a part of the DNA
binding domain (Fig. 4C). We infer that this mutant is func-
tioning as a dominant negative IRF-3 by squelching the crit-
ical co-factor(s). During the course of this study, it was re-
ported that a GST-fused IRF-3 protein can bind to the IFN-
K4 promoter and PRDIII of the IFN-L promoter, and that
IRF-3 cooperates with RelA(p65) [30]. These results are con-
sistent with ours, and one may speculate that the promoter
recruits many factors such as IRF-3, CBP/p300, NF-UB and
others, so as to form an enhanceosome [28] to ensure e⁄cient
activation of this gene.
In conclusion, our present data may reveal a mechanism of
the virus-induced activation of IFN-L gene transcription, in
which IRF-3 interacts with and activates the promoter,
through nuclear translocation, phosphorylation and interac-
tion with CBP/p300. Thus, IRF-3 may be the long-thought
transcription factor regulating the initial phase of IFN gene
transcription. Further work is in progress to characterize fur-
ther the nature of V-IRF-3, to identify the candidate protein
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Fig. 4. A: Expression of IRF-3 mRNA. 3T3/control or 3T3/IRF-3
cells were treated with NDV. Total RNA was prepared at each time
point indicated and subjected to Northern blotting analysis. B: Ef-
fect of IRF-3 overexpression on IFN-L mRNA induction. The same
RNA was loaded as in A. The mRNA levels were measured using
the imaging analyzer (Fujix BAS5000) and the level of IFN-L
mRNA was normalized by taking the ratio to that of the L-actin
mRNA. The obtained ratio at the peak point of 3T3/control cells
was taken to be 1 and plotted in the graph. C: IRF-3 enhances the
luciferase activity driven by the IFN-L promoter region. Cell lysates
were prepared after 18 h of NDV infection. Protein concentrations
of the lysates were adjusted and used for the luciferase assay. In co-
expression experiments, 0.02 Wg of pAct3 was co-transfected with
0.2 or 2.0 Wg of pAct3dN. The histogram shows the mean of two
independent experiments, and error bars show standard deviations.
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kinase for IRF-3, as well as to generate mice de¢cient in the
IRF-3 gene to elucidate further the contribution of this factor
in the host defense.
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